| GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults DB Allen, P Backeljauw, M Bidlingmaier, BMK Biller, M Boguszewski, ... European Journal of Endocrinology 174 (2), P1-P9, 2016 | 235 | 2016 |
| A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid … SB Cohen, R Alten, H Kameda, T Hala, SC Radominski, MI Rehman, ... Arthritis research & therapy 20, 1-13, 2018 | 59 | 2018 |
| Efficacy, safety, and tolerability of flexibly dosed ziprasidone in children and adolescents with mania in bipolar I disorder: a randomized placebo-controlled replication study RL Findling, S Atkinson, M Bachinsky, Y Raiter, P Abreu, C Ianos, ... Journal of Child and Adolescent Psychopharmacology 32 (3), 143-152, 2022 | 4 | 2022 |
| Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised … RM Fleischmann, W Saikali, S Lakhanpal, DF Alvarez, DS Cox, CA Ianos, ... The Lancet Rheumatology 5 (9), e532-e541, 2023 | 2 | 2023 |
| A comparative study assessing multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in active rheumatoid arthritis—A randomised clinical trial R Fleischmann, W Saikali, S Lakhanpal, DF Alvarez, DS Cox, CA Ianos, ... Available at SSRN 4337374, 2023 | 1 | 2023 |
| Serum Troponin I Assessments in 5-to 30-Year-Olds After BNT162b2 Vaccination TE Albertson, C Hansen, S Bihari, J Gayed, X Xu, JA Simón-Campos, ... Infectious Diseases and Therapy 13 (4), 699-714, 2024 | | 2024 |
| Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data J Dreyfus, S Munnangi, C Bengtsson, B Correia, R Figueiredo, JH Stark, ... Vaccine 42 (5), 1094-1107, 2024 | | 2024 |
| A Comparative Study Assessing Multiple Switching between the Biosimilar Adalimumab PF-06410293 and Reference Adalimumab in Active Rheumatoid Arthritis—A Randomised Clinical Trial K Fleischmann, Roy and Saikali, Wassim and Lakhanpal, Sharad and Alvarez ... Lancet, 2023 | | 2023 |
| Multiple Switching Between the Biosimilar Adalimumab PF-06410293 (Abrilada™) and Reference Adalimumab (Humira®)in Combination with Methotrexate in Patients with Moderately to … KWWZ Roy Fleischmann, Sharad Lakhanpal, WASSIM Saikali, Daniel Alvarez ... ACR Convergence 2022, 2022 | | 2022 |
| 26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent … S Atkinson, M Bachinsky, Y Raiter, P Abreu, C Ianos, P Chappell, ... Journal of Child and Adolescent Psychopharmacology 32 (8), 453-458, 2022 | | 2022 |
| Multiple Switching Between the Biosimilar Adalimumab PF-06410293 (Abrilada (TM)) and Reference Adalimumab (Humira (R)) in Combination with Methotrexate in Patients with … R Fleischmann, S Lakhanpal, W Saikali, D Alvarez, DS Cox, C Ianos, ... ARTHRITIS & RHEUMATOLOGY 74, 3145-3147, 2022 | | 2022 |
| Stanley B. Cohen1, Rieke Alten2, Hideto Kameda3, Tomas Hala4, Sebastiao C. Radominski5, Muhammad I. Rehman6 R Palaparthy, K Schumacher, S Schmitt, SY Hua, C Ianos, KL Sewell10 margin 12, 15.0, 2018 | | 2018 |
| The Effect of Regulatory Definitions on Mining Social Media for Adverse Events: A Real-World Examination M Ibara, S Stergiopoulos, J Van Stekelenborg, AC Ianos, R Ruben, P Naik, ... DRUG SAFETY 38 (10), 950-950, 2015 | | 2015 |
| 15th ISoP Annual Meeting “Cubism in Pharmacovigilance” Prague, Czech Republic 27-30 October, 2015 https://doi.org/10.1007/s40264-015-0346-0, 2015 | | 2015 |
